Our Discovery Development

MD1103 is intended to be a symptomatic drug focused on the treatment of autism spectrum disorders. MD1103 is intended to have an impact of certain core symptoms of autism including social withdrawal and apathy. MedDay is currently planning to start the clinical proof of concept study in 50 patients. (The name of the molecule and mechanism of action are undisclosed).

MedDay SA au capital de 116 660 €
Siège social : 96 Boulevard Haussmann 75008 Paris
RCS PARIS 534 957 865
Publication Director : Dr Frédéric Sedel